Enantioselective Synthesis Of

Total Page:16

File Type:pdf, Size:1020Kb

Enantioselective Synthesis Of ENANTIOSELECTIVE SYNTHESIS OF PHORACANTHOLIDE I, MEXILETINE, ENCIPRAZINE, ESMOLOL, ATENOLOL, XIBENOLOL VIA α- AMINOXYLATION OF ALDEHYDE AND APPLICATION OF RECYCLABLE CATALYSIS IN ORGANIC TRANSFORMATION A THESIS SUBMITTED TO THE UNIVERSITY OF PUNE FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN CHEMISTRY BY MOHSINKHAN YASEENKHAN PATHAN DR. SHAFEEK A. R. MULLA (RESEARCH GUIDE) CHEMICAL ENGINEERING AND PROCESS DEVELOPMENT DIVISION, NATIONAL CHEMICAL LABORATORY, PUNE- 411008, INDIA APRIL 2014 Mr. Yaseenkhan Sajjankhan Pathan Mrs. Farjana Yaseenkhan Pathan NATIONAL CHEMICAL LABORATORY DR. SHAFEEK A. R. MULLA Senior Scientist Ph.D. FMASc. AvH Fellow (Germany), JSPS Fellow (Japan) Chemical Engineering & Process Development Division Dr. Homi Bhabha Road, Pune – 411 008, India Tel.:+91-20-25902316, Fax:+91-20-25902676 E-mail : [email protected]/[email protected] CERTIFICATE Certified that the work incorporated in the thesis entitled “Enantioselective Synthesis of Phoracantholide I, Mexiletine, Enciprazine, Esmolol, Atenolol, Xibenolol via α- Aminoxylation of Aldehyde and Application of Recyclable Catalysis in Organic Transformation” was carried out by the candidate under my supervision. Such material as had been obtained from other sources has been duly acknowledged in the thesis. April 2014 (Dr. Shafeek. A. R. Mulla) Pune Research Guide NATIONAL CHEMICAL LABORATORY DECLARATION I here by declare that the thesis entitled “Enantioselective Synthesis of Phoracantholide I, Mexiletine, Enciprazine, Esmolol, Atenolol, Xibenolol via α-Aminoxylation of Aldehyde and Application of Recyclable Catalysis in Organic Transformation” submitted for the degree of Doctor of Philosophy in Chemistry to the University of Pune, has not been submitted by me to any other university or institution. This work was carried out at the National Chemical Laboratory, Pune, India. April 2014 Mohsinkhan Yaseenkhan Pathan Pune CE & PD Division, National Chemical Laboratory, Dr. Homi Bhabha Road Pune – 411 008, INDIA CONTENTS Page No. Acknowledgment ……………………………………………………… i Abbreviations ……………………………………………………… iii General Remarks ……………………………………………………… vi Abstract ……………………………………………………… vii CHAPTER I Enantioselective synthesis of (S)-Phoracantholide I and (R)- Mexiletine via α-aminoxylation of aldehyde catalyzed by L- proline Section I Enantioselective synthesis of (S)-Phoracantholide I 1.1.1 Introduction ………………………………………... 2 1.1.2 Review of literature ………………………………... 3 1.1.3 Present work ………………………………………. 7 1.1.3.1 Objectives ..………………………………………... 7 1.1.3.2 Proline-catalyzed α-aminoxylation ……………….. 8 1.1.3.3 Possible Mechanism for L-proline catalyzed asymmetric α-aminoxylation of aldehyde …………. 10 1.1.4 Results and discussion …………………………….. 11 1.1.4.1 Enantioselective synthesis of Phoracantholide I …... 12 1.1.5 Conclusion ………………………………………… 24 1.1.6 Experimental Section ……………………………… 24 Section II Enantioselective synthesis of (R)-Mexiletine 1.2.1 Introduction ………………………………………... 32 1.2.2 Review of literature ………………………………... 33 1.2.3 Present work ………………………………………. 40 1.2.3.1 Objectives ..………………………………………... 40 1.2.4 Results and discussion …………………………….. 40 1.2.4.1 Enantioselective synthesis of Mexiletine ………….. 41 1.2.5 Conclusion ………………………………………… 49 1.2.6 Experimental Section ……………………………… 50 1.2.7 References …………………………………………. 55 CHAPTER II Enantioselective synthesis of (S)-Enciprazine, (S)-Esmolol, (S)- Atenolol and (S)-Xibenolol via α-aminoxylation of aldehyde catalyzed by L-proline 2.1 Introduction ………………………………………... 61 2.2 Review of literature ………………………………. 63 2.3 Present work ………………………………………. 69 2.3.1 Objectives …………………………………………. 69 2.4 Results and discussion …………………………….. 70 2.4.1 Enantioselective synthesis of Enciprazine ………… 71 2.4.2 Enantioselective synthesis of Esmolol ……………. 79 2.4.3 Enantioselective synthesis of Atenolol ……………. 86 2.4.4 Enantioselective synthesis of Xibenolol ……...…… 94 2.5 Conclusion ………………………………………… 100 2.6 Experimental section ……………………………… 100 2.7 References …………………………………………. 112 CHAPTER III Synthetic methodologies in the presence of silica supported dodecatungstophosphoric acid (DTP/SiO2) Section I Highly efficient heterogeneous reusable silica supported dodecatungstophosphoric acid catalyzed one-pot multi- component synthesis of α-aminophosphonates and bis- α- aminophosphonates and their bioevaluation 3.1.1 Introduction ……………………………………… 116 3.1.2 Review of literature ………………………………. 117 3.1.3 Present work ………………………………………. 119 3.1.3.1 Objectives …………………………………………. 119 3.1.4 Results and discussion ……………………………. 120 3.1.5 Conclusion ………………………………………… 129 3.1.6 Experimental section ……………………………… 130 3.1.6.1 General Procedure for the preparation of DTP/SiO2-- 130 3.1.6.3 Antitubercular testing using XTT Reduction menadione assay protocol …………………………. 131 3.1.6.4 Cytotoxicity evaluation using MTT Reduction menadione assay protocol………………………… 132 3.1.7 Spectra …...………………………………………. 143 Section II A novel and efficient synthesis of azaarene-substituted 3- hydroxy-2-oxindoles via sp3 C-H functionalization of 2-methyl azaarenes and (2-azaaryl)methanes over heterogeneous, reusable silica-supported dodecatungstophosphoric acid catalyst 3.2.1 Introduction …………………………………… 167 3.2.2 Review of literature ………………………………. 169 3.2.3 Present work ………………………………………. 170 3.2.3.1 Objectives …………………………………………. 170 3.2.4 Results and discussion ……………………………. 171 3.2.5 Conclusion ………………………………………… 179 3.2.6 Experimental section ……………………………… 179 3.2.7 Spectra ….. ………………………………………. 196 Section III A facile and highly efficient one-pot multi-component synthesis of azaarene-substituted 3- substituted-2-oxindoles via sp3 C-H functionalization of 2-methyl azaarenes and (2- azaaryl)methanes over reusable silica-supported dodecatungstophosphoric acid catalyst 3.3.1 Introduction ……………………………………… 227 3.3.2 Present work ………………………………………. 229 3.3.2.1 Objectives …………………………………………. 229 3.3.3 Results and discussion ……………………………. 230 3.3.4 Conclusion ………………………………………… 236 3.3.5 Experimental section ……………………………… 237 3.3.6 Spectra ….. ………………………………………. 250 3.3.7 References ………………………………………… 276 CHAPTER IV Synthetic methodologies using ethylammonium nitrate (EAN) as an ionic liquid Section I Solvent free, highly efficient one-pot multi-component synthesis of 1-amido- and 1-carbamato-alkyl naphthols/phenols catalyzed by ethylammonium nitrate as reusable ionic liquid under neat reaction condition at ambient temperature 4.1.1 Introduction ……………………………………… 284 4.1.2 Review of literature ………………………………. 285 4.1.3 Present work ……………………………………… 288 4.1.3.1 Objectives …………………………………………. 288 4.1.4 Results and discussion ……………………………. 289 4.1.5 Conclusion ………………………………………… 296 4.1.6 Experimental section ……………………………… 297 4.1.6.1 A typical procedure for the synthesis of Ethyl ammonium nitrate (EAN) ionic liquid……………... 297 4.1.7 Spectra ……………………………………………. 308 Section II Efficient, rapid synthesis of bis(indolyl)methane using ethyl ammonium nitrate as an ionic liquid 4.2.1 Introduction ………………………………………... 332 4.2.2 Review of literature ………………………………. 333 4.2.3 Present work ……………………………………… 336 4.2.3.1 Objectives …………………………………………. 336 4.2.4 Results and discussion ……………………………. 336 4.2.5 Conclusion ………………………………………… 343 4.2.6 Experimental section ……………………………… 343 4.2.7 Spectra for selected compounds ……………... 351 4.2.8 References ………………………………………… 353 List of Publications ………………………………... 360 Acknowledgment All praise to Almighty Allah, the source of knowledge and wisdom within and beyond our comprehension and WHO bestowed His continuous boundless bounty upon me, blessed with courage of facing problems and obstacles, determination, and strength to complete this work. My deepest gratitude goes first to my research guide Dr. Shafeek A. R. Mulla for his constant support and encouragement during the course of Ph. D. work. It has been an intellectually stimulating and rewarding experience to work with him. We experienced together all the ups and downs of routine work, shared the happiness of success and the depression of failure. I would like to express my sincere gratitude and respect to Dr. V. V. Ranade, Deputy Director and Chair, CEPD Division, NCL. I also wish express deep sense of gratitude to Dr. B. D. Kulkarni, former Deputy Director and Head, CEPD, NCL. I would like to extend my special thanks to Dr. Sourav Pal, Director, NCL for allowing me to carry out research and extending all possible infrastructural facilities and permitting me to present this work in the form of a Ph.D. thesis. I thank NMR group and elemental analysis group for their help in obtaining the analytical data and also Dr. D. Sarkar and his group for the bioevaluation. I thank library staff, chemical stores, purchase staff, glass blowing section NCL for their cooperation. I thank CEPD office staff Mr. Raheja, Mr. Bhosale and Mr. Kakade for their cooperation. I thanks to Dr. C. G. Suresh, chair, Student Academic Office and staff Mrs. Puranik, Mrs. Kolhe, Mr. Pavithran and I also thank PG section of Pune University for their cooperation and help. I am extremely thankful to Dr. C. S. Gopinath, and Prof. A. K. Nikumbh, (Dept. of Chemistry, University of Pune) for their valuable help and suggestions during my research work. I also thank to Dr. A. Sudalai, Dr. Tarek Salama, Dr. Imran Rahman, Dr. M. S. Qureshi for their invaluable guidance and memorable suggestion and also to my college teachers Dr. R. P. Pawar, Head department of chemistry, Deogiri College, Aurangabad as well to Dr. W. N. Jadhav, Head department of chemistry, DSM college, parbhani for inspiring me towards
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,381,189 B2 Green Et Al
    US009381189B2 (12) United States Patent (10) Patent No.: US 9,381,189 B2 Green et al. (45) Date of Patent: Jul. 5, 2016 (54) INGREDIENTS FOR INHALATION AND (56) References Cited METHODS FOR MAKING THE SAME U.S. PATENT DOCUMENTS (75) Inventors: Matthew Michael James Green, 4,582,265 A * 4/1986 Petronelli ....................... 241.95 Wiltshire (GB); Richard Michael Poole, 6,257,233 B1 7/2001 Burr et al. 2004/01 18007 A1* 6/2004 Chickering et al. ............ 34/360 Wiltshire (GB) 2006, O257491 A1* 11, 2006 Morton et al. ... 424/489 (73) Assignee: VECTURA LIMITED, Wiltshire (GB) 2008/0063719 A1 3/2008 Morton et al. ................ 424/489 (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 EP O709086 A2 5, 1996 U.S.C. 154(b) by 641 days. EP 14981 16 A1 1, 2005 GB 2387781 A 10, 2003 JP 2005298.347 10/2005 (21) Appl. No.: 13/514,672 JP 200954.1393 11, 2009 JP 2012,542618 6, 2012 (22) PCT Fled: Dec. 8, 2010 WO 96.23485 A1 8, 1996 WO 9703649 A1 2, 1997 (86) PCT NO.: PCT/GB2O10/052053 WO O2OO197 A1 1, 2002 WO O243701 A2 6, 2002 S371 (c)(1), WO 2005105043 A2 11/2005 Aug. 20, 2012 WO 2007053904 A1 5/2007 (2), (4) Date: WO 2008.000482 1, 2008 (87) PCT Pub. No.: WO2O11AO70361 WO 2009095684 A1 8, 2009 OTHER PUBLICATIONS PCT Pub. Date: Jun. 16, 2011 Brunauer et al. "Adsorption of Gases in Multimolecular Layers'. J. (65) Prior Publication Data Am.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Self-Measured Compared to Office
    Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Supplemental Tables and Figures Part 1: Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension Table 1.1 Electronic search terms used for the current meta-analysis (Part 1 – Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension). PubMed Search (Blood Pressure Monitoring, Ambulatory [mesh] OR self care [mesh] OR telemedicine [mesh] OR patient participation [tiab] OR ambulatory [tiab] OR kiosk [tiab] OR kiosks [tiab] OR self-monitor* [tiab] OR self-measure* [tiab] OR self-care* [tiab] OR self-report* [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR home monitor* [tiab] OR telehealth [tiab] OR tele-health [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR telemedicine [tiab] OR patient-directed [tiab] OR Blood pressure monitoring “patient directed” [tiab] OR HMBP [tiab] OR SMBP [tiab] OR home [tiab] OR white coat [tiab] OR concept + Self Care concept ((patient participation [ot] OR ambulatory [ot] OR kiosk [ot] OR kiosks [ot] OR self-monitor* [ot] OR self-measure* [ot] OR self-care* [ot] OR self-report* [ot] OR telemonitor* [ot] OR tele-monitor* [ot] OR home monitor* [ot] OR telehealth [ot] OR tele-health [ot] OR telemonitor* [ot] OR tele- monitor* [ot] OR telemedicine [ot] OR patient-directed [tiab] OR “patient directed” [tiab]
    [Show full text]
  • (12) Patent Application Publication (48) Pub
    US 20090226407A9 (19) United States (10) Pub. No.: US 2009/0226407 A9 (12) Patent Application Publication (48) Pub. Date: Sep. 10, 2009 L0ScalZ0 et al. CORRECTED PUBLICATION (54) METHODS OF TREATING VASCULAR (60) Provisional application No. 60/179,020, filed on Jan. DISEASES CHARACTERIZED BY NITRC 31, 2000. Provisional application No. 60/162,230, OXIDE INSUFFICIENCY filed on Oct. 29, 1999. Provisional application No. 60/179,020, filed on Jan. 31, 2000. Provisional appli (76) Inventors: Joseph Loscalzo, Dover, MA (US); cation No. 60/162,230, filed on Oct. 29, 1999. Joseph A. Vita, Hingham, MA (US); Michael D. Loberg, Boston, MA (US); Publication Classification Manuel Worcel, Boston, MA (US) (51) Int. Cl. Correspondence Address: A6II 38/43 (2006.01) WILMERHALEANTROMED AOIN 43/04 (2006.01) 1875 PENNSYLVANIAAVE, NW (52) U.S. Cl. .............................................. 424/94.1: 514/23 WASHINGTON, DC 20006 (US) (21) Appl. No.: 10/692,724 (57) ABSTRACT (22) Filed: Oct. 27, 2003 The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency Prior Publication Data by administering atherapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nit (15) Correction of US 2004/0105850 A1 Jun. 3, 2004 rosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated See (60) Related U.S. Application Data. endothelin antagonist, nitrosated angiotensin II receptor (65) US 2004/0105850 A1 Jun. 3, 2004 antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at Related U.S. Application Data least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers (60) Continuation-in-part of application No.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Therapeutic Combination and Use of Dll4 Antagonist Antibodies and Anti-Hypertensive Agents
    (19) TZZ Z_T (11) EP 2 488 204 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/395 (2006.01) A61P 35/00 (2006.01) 06.04.2016 Bulletin 2016/14 A61P 9/12 (2006.01) (21) Application number: 10824244.7 (86) International application number: PCT/US2010/053064 (22) Date of filing: 18.10.2010 (87) International publication number: WO 2011/047383 (21.04.2011 Gazette 2011/16) (54) THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS THERAPEUTISCHE KOMBINATION UND VERWENDUNGG MIT DLL4-ANTAGONISTISCHE ANTIKÖRPER UND MITTEL GEGEN BLUTHOCHDRUCK COMBINAISON THÉRAPEUTIQUE ET UTILISATION D’ANTICORPS ANTAGONISTES DE D LL4 ET D’AGENTS ANTI-HYPERTENSEURS (84) Designated Contracting States: US-A1- 2009 221 549 AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • SMITH D C ET AL: "222 A first-in-human, phase I PL PT RO RS SE SI SK SM TR trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with (30) Priority: 16.10.2009 US 252473 P advanced solid tumors", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, (43) Date of publication of application: OXFORD, GB, vol. 8, no. 7, 1 November 2010 22.08.2012 Bulletin 2012/34 (2010-11-01), page 73, XP027497910, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(10)71927-3 (60) Divisional application: [retrieved on 2010-11-01] & Smith et al: "A 16155324.3 first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem (73) Proprietor: Oncomed Pharmaceuticals, Inc.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0293552 A1 Gorczynski (43) Pub
    US 20070293552A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0293552 A1 Gorczynski (43) Pub. Date: Dec. 20, 2007 (54) ANTIHYPERTENSIVE THERAPY METHOD Publication Classification (76) Inventor: Richard J. Gorczynski, Westminster, (51) Int. Cl. CO (US) A6II 3/42 (2006.01) (52) U.S. Cl. .............................................................. S14/378 Correspondence Address: (57) ABSTRACT HARNESS, DICKEY, & PIERCE, P.L.C Methods and therapeutic combinations are provided for 7700 BONHOMME, STE 400 lowering blood pressure in a Subject exhibiting resistance to ST. LOUIS, MO 63105 (US) a baseline antihypertensive therapy with one or more drugs, or a subject having diabetes and/or chronic kidney disease. A method of the invention comprises administering, in some (21) Appl. No.: 11/761,499 embodiments adjunctively with a modified baseline therapy, a compound of formula (I) as defined herein. A therapeutic (22) Filed: Jun. 12, 2007 combination of the invention comprises a compound of formula (I); at least one diuretic; and at least one antihy pertensive drug selected from ACE inhibitors, angiotensin II Related U.S. Application Data receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers; wherein the at least one diuretic (60) Provisional application No. 60/813.966, filed on Jun. and/or the at least one antihypertensive drug are present at 15, 2006. substantially less than a full dose. US 2007/0293552 A1 Dec. 20, 2007 ANTHYPERTENSIVE THERAPY METHOD signaling pathways. While antagonism of the ETA receptor is known to reduce endothelin-mediated vasoconstriction, 0001. This application claims the benefit of U.S. provi antagonism of the endothelin-B (ET) receptor can block sional application Ser.
    [Show full text]